SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 91 filers reported holding SYROS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 6.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $11,000 | -54.2% | 11,278 | -45.1% | 0.00% | – |
| Q1 2022 | $24,000 | -71.1% | 20,554 | -18.8% | 0.00% | -100.0% |
| Q4 2021 | $83,000 | -78.7% | 25,316 | -70.9% | 0.00% | -80.0% |
| Q3 2021 | $389,000 | -72.3% | 86,990 | -66.3% | 0.01% | -68.8% |
| Q2 2021 | $1,406,000 | +621.0% | 257,997 | +891.3% | 0.02% | +700.0% |
| Q1 2021 | $195,000 | -52.9% | 26,025 | -31.7% | 0.00% | -66.7% |
| Q4 2020 | $414,000 | +444.7% | 38,112 | +345.7% | 0.01% | +500.0% |
| Q3 2020 | $76,000 | -62.6% | 8,551 | -55.2% | 0.00% | -75.0% |
| Q2 2020 | $203,000 | +20200.0% | 19,079 | +11393.4% | 0.00% | – |
| Q1 2020 | $1,000 | -66.7% | 166 | -68.4% | 0.00% | – |
| Q4 2018 | $3,000 | -87.0% | 526 | -72.3% | 0.00% | -100.0% |
| Q3 2018 | $23,000 | -80.7% | 1,898 | -83.7% | 0.00% | -83.3% |
| Q2 2018 | $119,000 | -20.1% | 11,665 | +15.2% | 0.01% | -25.0% |
| Q3 2017 | $149,000 | – | 10,126 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures Fund IV General Partner LLC | 4,806,656 | $87,241,000 | 14.92% |
| Aisling Capital LLC | 908,565 | $16,490,000 | 3.89% |
| Foresite Capital Management III, LLC | 150,000 | $2,723,000 | 1.87% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,095,220 | $38,028,000 | 1.50% |
| Redmile Group, LLC | 946,182 | $15,058,000 | 1.44% |
| Casdin Capital, LLC | 50,000 | $908,000 | 0.90% |
| Eventide Asset Management | 150,000 | $2,723,000 | 0.17% |
| Weiss Multi-Strategy Advisers LLC | 45,857 | $832,000 | 0.06% |
| Baker Brothers Advisors | 204,465 | $3,711,000 | 0.04% |
| Alyeska Investment Group, L.P. | 70,000 | $1,271,000 | 0.01% |